A panelist discusses how a 76-year-old patient with neovascular age-related macular degeneration (nAMD) initially stable on bevacizumab developed recurrent subretinal fluid requiring a switch to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback